Feed RCUS
RC

Arcus Biosciences, Inc. RCUS · NYSE

$18.18 -2.31% (-$0.43)

Market cap
$2.29B
Enterprise value
$2.25B
P/E
-
Forward P/E
-
PEG
-
P/S
19.5x
P/FCF
-
EV/EBITDA
-
ROIC
-65.8%
Gross margin
94.0%
Net margin
-386.3%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.81
Free float
74.9%

About the company

Arcus Biosciences, Inc. (RCUS) is an American biotechnology company focused on researching and developing new drugs for the treatment of oncology and inflammatory diseases. The company specializes in discovering innovative therapeutic drugs based on immunotherapy and cell growth pathway inhibition. Its research and development efforts are aimed at boosting the immune system's ability to fight against cancer cells and inflammatory processes. Arcus Biosciences collaborates with pharmaceutical companies and academic institutions in the discovery and development of new drugs and therapies. The company aims to bring innovative treatment options to patients facing challenging and difficult-to-treat diseases. Arcus Biosciences, Inc. is recognized for its research potential and influential position in the field of immuno-oncology. Arcus Biosciences, Inc. (RCUS) shares may represent an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with an innovative portfolio of research in oncology and immunotherapy.

Sector

Healthcare

Industry

Biotechnology

CEO

Terry J. Rosen

Employees

601

Headquarters

Hayward

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 30% a year over the last 3 years.
  • What to watch: Analysts expect revenue to fall by 70% this fiscal year.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: $150.0M against $114.0M.
  • What to watch: It passes only 0 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy